We found that depletion of CD8+ T cells abrogated the DT2216-mediated tumor inhibitory effect (Fig. 3f and Supplementary Fig. 6b), supporting the notion that DT2216-mediated inhibition of tumor growth in syngeneic models is via CD8+ T cells. The gene discussed is CD8A; the disease is neoplasm.